Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Pirfenidone + Nintedanib in IPF
NCT02598193Phase 4Completed
- Sponsor
- Roche
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 4 trial of pirfenidone, nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Roche. Started Jan 2016; status: completed.
02
Drugs
pirfenidonenintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02598193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598193.